ACE2 and SARS-CoV-2 Infection: Might GLP-1 Receptor Agonists Play a Role?

Recently it has been hypothesized that DPP4 inhibitors can have a beneficial effect on SARS-CoV-2 infection through immunoregulating activity. Experimental study on streptozotocintreated rats showed that liraglutide was able to stimulate the expression of pulmonary angiotensin converting enzyme 2 (A...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes therapy 2020-09, Vol.11 (9), p.1909-1914
Main Authors: Monda, Vincenzo M., Porcellati, Francesca, Strollo, Felice, Gentile, Sandro
Format: Article
Language:English
Subjects:
ACE inhibitors
Cardiology
Commentary
COVID-19
Diabetes
Drug therapy
Endocrinology
Hypoglycemic agents
Internal Medicine
Medicine
Medicine & Public Health
Pathophysiology
Pharmacology, Experimental
Severe acute respiratory syndrome coronavirus 2
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recently it has been hypothesized that DPP4 inhibitors can have a beneficial effect on SARS-CoV-2 infection through immunoregulating activity. Experimental study on streptozotocintreated rats showed that liraglutide was able to stimulate the expression of pulmonary angiotensin converting enzyme 2 (ACE2) and angiotensin (1–7). Liraglutide modulated different elements of the renin angiotensin system (RAS), significantly increasing ACE2 and Mas receptor (MasR) mRNA expression in pup lungs from food-restricted mothers. Some action mechanisms support the hypothesis of a protective action of GLP1R agonists, capable of mitigating a more serious clinical course among SARS-CoV2-infected individuals with T2DM.
ISSN:1869-6953
1869-6961
DOI:10.1007/s13300-020-00898-8